Intense pulsed light therapy for ocular surface diseases
AbstractIntense pulsed light (IPL) is a non-laser, high-intensity light source that has been shown to play a valuable role in dermatology and has been adopted in ophthalmology for treating meibomian gland dysfunction (MGD). In this review, we discuss the mechanism of action of IPL, including its benefits in ophthalmology. IPL therapy has been shown to improve tear film stability, meibomian gland (MG) function, and subjective symptoms of ocular dryness in MGD patients. Moreover, emerging evidence suggests that IPL therapy is beneficial for other ocular surface diseases, such as blepharitis and chalazia. Hence, it can be inf...
Source: Lasers in Medical Science - April 24, 2024 Category: Laser Surgery Source Type: research
Atopic Keratoconjunctivitis: Pathophysiology, Clinic, and Potential New Therapeutic Concepts
Klin Monbl Augenheilkd. 2024 Apr 11. doi: 10.1055/a-2244-2885. Online ahead of print.ABSTRACTAtopic dermatitis (AD) is a chronic recurrent inflammatory skin disease with a bipolar age distribution in childhood, adolescence and middle adulthood. Up to 50% of AD patients show ocular involvement, which can be potentially sight threatening. Clinically, the majority of cases present with atopic blepharo(kerato)conjunctivitis or atopic keratoconjunctivitis (AKC); other clinical variants from this group of inflammatory ocular surface diseases are keratoconjunctivitis vernalis in childhood and adolescence and allergic conjunctivit...
Source: Klinische Monatsblatter fur Augenheilkunde - April 11, 2024 Category: Opthalmology Authors: Thabo Lapp Caroline Mann Thilo Jakob Thomas Reinhard Philip Christian Maier Source Type: research
Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis
ConclusionsThis study affirms the current scientific community's stance that immunomodulators effectively treat clinical signs, including blepharitis, conjunctival hyperemia, edema, papillae, and corneal damage in severe ocular allergic disease. (Source: International Ophthalmology)
Source: International Ophthalmology - March 24, 2024 Category: Opthalmology Source Type: research
Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials
Demodex blepharitis, often overlooked in ocular surface disease, involves Demodex mites, prevalent ectoparasites on human skin. Current treatments may not effectively eliminate these mites, prompting a need for targeted therapies. Lotilaner, an antiparasitic agent, shows promise. This systematic review and meta-analysis assesses 0.25% lotilaner ophthalmic solution's efficacy in reducing Demodex mite populations and its impact on ocular surface inflammation in Demodex blepharitis patients. (Source: Contact Lens and Anterior Eye)
Source: Contact Lens and Anterior Eye - March 21, 2024 Category: Opthalmology Authors: Syed Muhammad Muneeb Akhtar, Areeba Fareed, Muhammad Sohaib Asghar, Munazza Mumtaz, Sehajpreet Kaur Tags: Review Article Source Type: research
Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies
This review aims to assess the safety and efficacy of Lotilaner in the treatment of Demodex Blepharitis. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - March 19, 2024 Category: Opthalmology Authors: Muhammad Talha, Mohammad Haris Ali, Eeshal Fatima, Arsalan Nadeem, Abdullah Ahmed, Abdulqadir J. Nashwan Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
Xdemvy < sup > TM < /sup > (Lotilaner Ophthalmic Solution) 0.25% Topical Solution for the Treatment of < em > Demodex < /em > Blepharitis
Skinmed. 2024 Mar 18;22(1):61-66. eCollection 2024.ABSTRACTXdemvyTM (lotilaner ophthalmic solution) 0.25% topical solution was recently approved for the treatment of Demodex blepharitis in adults aged ≥18 years. As an antiparasitic agent, lotilaner selectively inhibits gamma-aminobutyric acid chloride channels specific to the parasite and induces spastic paralysis, leading to death of Demodex blepharitis mites. In two randomized, double-masked, vehicle-controlled, multi-center, phase-3 clinical trials (Saturn-1 and Satuirn-2), lotilaner 0.25% topical solution was investigated for the treatment of Demodex blepharitis. Pat...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Aditya K Gupta Avantika Mann Kimberly Vincent William Abramovits Source Type: research
